Myositis, Inclusion Body

• 

  Subject Areas on Research

  • Apolipoprotein E and neuromuscular disease: a critical review of the literature. 
  • Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. 
  • Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. 
  • Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. 
  • Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis. 
  • Sonographic similarities of inclusion body myositis and myotonic dystrophy. 
  • VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD.